Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions

Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.

The main questions it aims to answer :

• What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
• Are there any potential drug interactions between dietary supplements and anticancer medications?

Participants will:

• Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
• Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
• Report any perceived adverse effects related to dietary supplement use to assess tolerance.
• Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

Inclusion Criteria:

• Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
• Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
• Adult patients : >=18

Exclusion Criteria:

• Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
• Failure or refusal to provide written informed consent.